Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (April 2019)
11 slides from Niagen Bioscience's investor presentation, Apr 8, 2019
Slide 1: Investor FAQs Fourth Quarter 2018
hromaDex Investor FAQs Fourth Quarter 2018 See eee Nasdaq: CDXC | April 8, 2019
Slide 2: Strategy
STRATEGY « What do you mean by “technical feasibility” with respect to the Nestlé Health Science supply and license agreement? o There is a technical feasibility requirement in 2019. o The primary technical feasibility requirement is stability in a ready to drink format. o ChromaDex and Nestlé are w
Slide 3: How are you addressing counterfeit products?
« How are you addressing counterfeit products? o ChromaDex holds exclusive patent rights to nicotinamide riboside chloride (NIAGEN®). o One of our strategic priorities is to protect our intellectual property and to protect the credibility of NR as a Safe and efficacious NAD precursor. o We test prod
Slide 4: Financial
FINANCIAL e What was the split of Amazon versus Truniagen.com sales in Q4 2018? Have you seen faster growth on Truniagen.com? o We have not provided a split between websites, but Amazon is the bigger business. o Weare focused on optimizing both channels and driving recurring revenue. 9: COXC 4
Slide 5: What is the status of regulatory approval in international markets?
e What is the status of regulatory approval in international markets? ° ° We sell in Canada, Hong Kong, Macau, New Zealand, and Singapore. We have marketing claims approved by the Health Sciences Authority in Singapore and we continue to pursue additional claims. We will no longer provide specific e
Slide 6: Science
SCIENCE e What placebo-controlled human studies are underway, and what is being measured? o We finished the fourth quarter with about 170 signed research collaborations. © There are more than 100 peer-reviewed publications on the science of NR, of which five are human studies and three of these are
Slide 7: How do you think about competition from NMN?
How do you think about competition from NMN? © Strategically, we remain focused on the market opportunity for TRU NIAGEN® since published scientific data show NR is a safe and more effective way of increasing NAD levels than NMN. o NR has five published human clinical studies, while NMN has none. o
Slide 8: Other
OTHER ¢ What are the implications of the newly issued W.R. Grace patent for ChromaDex? o The crystal morphology patents for Form 1 and Form 2 of nicotinamide riboside chloride were recently issued to W.R. Grace (in Q1 2019). o WR. Grace supplies ChromaDex exclusively with nicotinamide riboside chlor
Slide 9: NR has Reached the Significant Milestone of Registered Human Studies
"NR has Reached the Significant Milestone of 33 Registered Human Studies) Preclinical 5 4 Clinical Health Research Outcomes : 4 published clinical studies of ; NIAGEN® led the way 33 studies are currently registered on clinicaltrials.gov New studies are now examining clinically relevant health At le
Slide 10: Neurological, Cardiovascular Health, and Obesity are the Most Prominent Human Clinical Research Areas
‘Neurological, Cardiovascular Health, and Obesity are the Most Prominent Human Clinical Research Areas f NIAGEN® NEUROLOGICAL CARDIOVASCULAR OBESITY OTHER APPENDIX B Human Studies 34% 28% 19% 19% Conditions Studied ~ Parkinson disease ~ Heart failure - Type 2 diabetes - Immunity/inflammation (Insuli
Slide 11: Contact Info
Contact Info Brianna Gerber Senior Director of FP&A and Investor Relations T: +1.949.344.3782 BriannaG@chromadex.com www.chromadex.com